Telix Pharmaceuticals Limited (TLX)
NASDAQ: TLX · Real-Time Price · USD
9.56
+0.11 (1.16%)
Jun 12, 2026, 4:00 PM EDT - Market closed

Telix Pharmaceuticals Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
3,2552,5375,155---
Market Cap Growth
-43.09%-50.78%----
Enterprise Value
3,5992,8635,075000
Last Close Price
9.567.4915.40---
PE Ratio
--157.79---
PS Ratio
4.053.169.98---
PB Ratio
7.846.1114.61---
P/FCF Ratio
--112.40---
P/OCF Ratio
--93.76---
EV/Sales Ratio
4.483.569.82---
EV/EBITDA Ratio
110.8955.9383.94---
EV/EBIT Ratio
186.6296.1491.98---
EV/FCF Ratio
--110.65---
Debt / Equity Ratio
1.081.080.980.110.120.88
Debt / EBITDA Ratio
9.139.135.960.78--
Debt / FCF Ratio
--7.850.53--
Net Debt / Equity Ratio
0.780.78-0.23-0.71-1.32-9.03
Net Debt / EBITDA Ratio
6.356.35-1.32-4.751.220.48
Net Debt / FCF Ratio
-5.40-5.40-1.74-3.241.490.32
Asset Turnover
0.760.760.851.480.860.05
Inventory Turnover
12.4312.4310.1914.0610.711.24
Quick Ratio
1.171.172.571.141.821.09
Current Ratio
1.431.432.781.412.021.25
Return on Equity (ROE)
-1.85%-1.85%14.83%5.40%-252.89%-187.51%
Return on Assets (ROA)
3.83%3.83%8.06%7.93%-52.07%-33.21%
Return on Invested Capital (ROIC)
6.15%6.15%16.43%16.04%-104.92%-60.55%
Return on Capital Employed (ROCE)
3.57%3.57%12.27%7.87%-74.58%-42.19%
Earnings Yield
--0.63%---
FCF Yield
--0.89%---
Buyback Yield / Dilution
2.12%2.12%-6.63%-4.21%-10.08%-9.69%
Total Shareholder Return
2.12%2.12%-6.63%-4.21%-10.08%-9.69%
SEC Filings: 10-K · 10-Q